Skip to content
Screener

Aurinia Pharmaceuticals AUPH Interest Income

Interest Income at other companies

Vera Therapeutics logo
Vera TherapeuticsVERA
$6.36M-8.0%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$5M-16.7%
Opko Health logo
Opko HealthOPK
$3.22M-2.0%
LQD
Liquidia CorporationLQDA
$1.77M+2.5%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$3.85M+27.0%
ALN
Alnylam PharmaceuticalsALNY
$28.14M+2.4%

Other financials

Income statement

See full
Revenue$83.2M+18.9%
Gross profit$76.7M+21.9%
Operating income$46.3M+131%
Net income$37.4M+73.9%
EPS (diluted)$0.28+75.0%

Balance sheet

See full
Cash & equivalents$179.8M+239%
Total debt$80.6M-17.7%
Total equity$614.9M+83.4%
Total assets$792.3M+57.6%

Cash flow

See full
Operating cash flow$52.6M+18.8%

Valuation

See full
Market cap$2.07B+35.7%
Enterprise value$1.98B+25.5%
P/E6.6×-18.6×
P/S6.7×+0.8×

Profitability

See full
Gross margin90.4%+0.8pp
Operating margin48.4%+28.4pp
Net margin100.8%+77.5pp

Returns & leverage

See full
Return on equity66.1%+48.8pp
Debt / equity0.1×-0.2×
Current ratio5.4×+0.2×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 8:16 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001600620-26-000062
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Other (income) expense, net(6,234)9,246(5,955)13,675
Total operating expenses36,87949,92573,16290,543
Income from operations46,34120,08387,76341,930
Interest income3,3933,1906,9086,759
Interest expense(948)(1,117)(1,960)(2,184)
Net income before income taxes48,78622,15692,71146,505
Income tax expense11,37264320,9421,648
Net income$37,414$21,513$71,769$44,857

Item 1. Financial Statements.

FAQ

What is Aurinia Pharmaceuticals's interest income?
Aurinia Pharmaceuticals (AUPH) reported interest income of $3.39M in Q2 2026.
How has Aurinia Pharmaceuticals's interest income changed year-over-year?
Aurinia Pharmaceuticals's interest income increased by 6.4% year-over-year, from $3.19M to $3.39M.
What is the long-term trend for Aurinia Pharmaceuticals's interest income?
Over 2 years (2022 to 2025), Aurinia Pharmaceuticals's interest income has grown at a 62.9% compound annual growth rate (CAGR), from $5.12M to $13.57M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.

Ask your AI about Aurinia Pharmaceuticals's interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude